AVADEL PHARMACEUTICALS (AVDL)

IE00BDGMC594 - Common Stock

14.86  -0.19 (-1.26%)

After market: 14.86 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (11/4/2024, 8:00:00 PM)

After market: 14.86 0 (0%)

14.86

-0.19 (-1.26%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-10.05%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.35B
Shares
PEN/A
Fwd PE21.37
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AVDL Daily chart

Company Profile

Avadel Pharmaceuticals PLC is a IE-based company operating in Pharmaceuticals industry. The company is headquartered in Dublin, Dublin and currently employs 154 full-time employees. Avadel Pharmaceuticals PLC is a biopharmaceutical company. The firm's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Company Info

AVADEL PHARMACEUTICALS

Block 10-1 Blanchardstown Corporate Park, Ballycoolin

DUBLIN DUBLIN D02

P: 35319015201

CEO: Gregory J. Divis

Employees: 154

Website: https://www.avadel.com/

AVDL News

News Image4 days ago - Market News VideoNoteworthy Thursday Option Activity: ROOT, AVDL, IGT
ChartMill News Image5 days ago - ChartmillWhich stocks are moving before the opening bell on Thursday?

Which stocks are moving before the opening bell on Thursday?

News Image5 days ago - Avadel Pharmaceuticals plcAvadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to...

News Image19 days ago - Avadel Pharmaceuticals plcAvadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and...

News Image2 months ago - Market News VideoRSI Alert: Avadel Pharmaceuticals (AVDL) Now Oversold
News Image2 months ago - Avadel Pharmaceuticals plcAvadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens – – 91% reported...

AVDL Twits

Here you can normally see the latest stock twits on AVDL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example